EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model

Maria Perez-Penco, Tara Elizabeth Scott iD, Emilie Sofie Engdal iD, Cristina Picon Jara, Gabriel Mira González iD, Lea Klingenberg Barfod iD, Kristoffer Staal Rohrberg iD, Frederik Otzen Bagger iD, Lasse Neukirch iD, Anne-Marie Carola Andersson iD, Peter Johannes Holst

International Journal of Molecular Sciences · 29.10.2026 · 27 (21) · 9717

DOI: 10.3390/ijms27219717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.10.2026. Verfasst von Maria Perez-Penco und 10 weiteren Autor:innen. Beteiligte Einrichtung: HERVolution Therapeutics, Symbion, 2000 Frederiksberg, Denmark. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Endogenous Retroviruses, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Innovation Council, European Innovation Council Accelerator, European Innovation Council Eurostars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human endogenous retrovirus-K (HERV-K/HML-2) has been associated with non-small cell lung cancer (NSCLC), but its functional relevance and the potential for HERV-directed immunotherapy remains unresolved. Here, we characterized HERV-K expression across 207 advanced NSCLC patient biopsies by total RNA-seq observing widespread expression of HERV-K Gag and Env antigen encoding sequences. The Env-ORF that disrupted HERV-K102 was strongly associated with interferon and antigen-presenting programs, identifying it as a marker of an immune-activated tumor state. shRNA-mediated knockdown of HERV-K in five NSCLC cell lines with distinct driver mutations impaired proliferation and survival. In separate experiments, exposure of these cell lines to treatment-related stressors, including cytokines (TNF-α and IFN-γ) and chemotherapy, revealed dynamic patterns of HERV-K protein accumulation with antigen expression retained, and in some cases increased. Immunotherapeutic targeting was performed using the ASB-XIV mouse NSCLC cell line and a murine ERV surrogate antigen using adenovirus to express murine leukemia virus (MLV) antigen on a mouse β-retroviral particle structurally related to HERV-K. This immunization was able to elicit significant protection against tumor challenge and additive benefit with anti-PD-L1 in therapeutic treatment, establishing proof-of-concept for ERV-targeted immunotherapy in a murine surrogate system rather than direct evidence of HERV-K-targeted efficacy. Our findings suggest an important role of HERV-K in NSCLC immunobiology and that adaptive immunity targeting HERV-K should be explored in the treatment of NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungEndogenous RetrovirusesLung NeoplasmsImmunotherapyAnimalsHumansMiceCell Line, TumorDisease Models, AnimalGene Products, env

Stichwörter der Autor:innen

HERV-Khuman endogenous retrovirusesimmune checkpoint inhibitorimmunotherapynon-small cell lung cancer

Substanzen

Gene Products, env

Autor:innen und Institutionen

  • HERVolution Therapeutics, Symbion, 2000 Frederiksberg, Denmark.
  • MDxCORE, Copenhagen University Hospital (Rigshospitalet), 2100 Copenhagen, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.

ORCID-Profile: Tara Elizabeth Scott, Emilie Sofie Engdal, Gabriel Mira González, Lea Klingenberg Barfod, Kristoffer Staal Rohrberg, Frederik Otzen Bagger, Lasse Neukirch, Anne-Marie Carola Andersson

Förderung

  • European Innovation Council
  • European Innovation Council Accelerator
  • European Innovation Council Eurostars

Zitieren

APA

Perez-Penco, M., Scott, T. E., Engdal, E. S., Picon Jara, C., González, G. M., Barfod, L. K., Rohrberg, K. S., Bagger, F. O., Neukirch, L., Andersson, A. C., & Holst, P. J. (2026). Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model. International Journal of Molecular Sciences, 27(21), 9717. https://doi.org/10.3390/ijms27219717

Vancouver

Perez-Penco M, Scott TE, Engdal ES, Picon Jara C, González GM, Barfod LK, et al. Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model. International Journal of Molecular Sciences. 2026;27(21):9717. doi:10.3390/ijms27219717

BibTeX
@article{PerezPenco2026,
  author = {Perez-Penco, Maria and Scott, Tara Elizabeth and Engdal, Emilie Sofie and Picon Jara, Cristina and González, Gabriel Mira and Barfod, Lea Klingenberg and Rohrberg, Kristoffer Staal and Bagger, Frederik Otzen and Neukirch, Lasse and Andersson, Anne-Marie Carola and Holst, Peter Johannes},
  title = {Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9717},
  doi = {10.3390/ijms27219717}
}
Kostenlos starten →